BioPharma Dive November 13, 2024
With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of obesity treatments.
Dive Brief:
- Metsera, already a well-funded biotech startup, added another $215 million to its coffers as investors responded to the promise of its obesity drug pipeline.
- Wellington Management and Venrock Healthcare Capital Partners led the latest round of financing, the company said Wednesday. New investors included “crossover” investors such as Fidelity Management & Research, Janus Henderson Investors and T. Rowe Price.
- The Series B financing brings the total raised for Metsera to more than $500 million. The company officially launched in April after raising $290 million in a financing led by Arch Venture Partners and Population Health...
Today's Sponsors
Today's Sponsor